Rhizen Pharma receives USFDA Orphan-Drug Designation for Tenalisib


Alembic Pharma Ltd announced that our Associate Company, Rhizen Pharmaceuticals S.A. (Rhizen) has released a Press Release announcing that the USFDA has granted Orphan-Drug Designation for Tenalisib (RP6530).

The company had informed the exchanges that USFDA has granted Fast Track Designation for Tenalisib (RP6530) to Rhizen.

NewsBarons is now active on WhatsApp. To receive news and updates on your handset, please click here and press send to subscribe.

Yash Ved
Yash Ved is a Senior Correspondent at NewsBarons and comes with a decade of experience across leading online and offline publications. A keen observer of the stock index movement, Yash also likes covering Real Estate and the BFSI sector. A financial management and Journalism student, Yash believes learning as a continuous journey and enjoys following the IT and the Pharmaceutical industry and has penned many articles on the subjects.